近日，在位于花都区花东镇的华润国际医药供应链（广东）项目建设现场，记者看到工程车辆往来穿 梭，施工井然有序推进。随着项目正式破土动工，一座面向粤港澳大湾区、辐射全国的现代化医药健康 物流枢纽正从蓝图加速迈向现实。 项目建设现场。 "项目以'智能运营、多元兼容、低碳示范'为核心，致力于成为粤港澳大湾区医药健康产业供应链的关 键节点。"该项目相关负责人表示，通过自动化、智能化系统的深度应用，预计可提升仓储分拣效率约 40%，同时项目将全力打造"近零碳示范园区"，践行绿色可持续发展理念。 自项目启动以来，省、市、区各级部门主动服务、精准支持，从配套路网建设、水土保持工程到审批流 程优化，提供"全方位、全天候、全流程"保障，推动项目前期手续高效办结，为工程建设按下"加速 键"。 据企业相关负责人介绍，该项目是华润医药商业服务"健康中国"战略、融入粤港澳大湾区建设的核心载 体，建成后将有效整合华南区域仓储资源，形成"1+4"全省协同网络，显著提升药品特别是急抢救药、 冷链药品的供应保障能力，同时为"港澳药械通"等跨境医药服务提供有力支撑。 该项目预计于2028年4月建成投产。届时，它不仅将大幅增强华润在华南医药物流领域 ...

"医药关乎生命，物流连接希望。将河南的枢纽优势转化为医药供应链的效率优势、安全优势，可以有 效助力健康河南建设。"1月28日，省政协委员、河南博之康医药集团有限公司董事长王丁普说。 王丁普说，河南既是医药生产流通大省，又是全国重要的综合交通枢纽。全省药品流通销售额约占全国 的7.3%，郑州机场货邮吞吐量稳居全国前列，高速公路、高铁、中欧班列、内河航运形成立体交通体 系，为发展医药多式联运奠定了坚实基础。然而，当前医药物流仍存在衔接不畅、数智化水平不高、专 业经营主体不足等问题。 为此，他建议构建高效联运体系，在郑州、南阳、周口等重点区域建设医药专用多式联运场站，推广标 准化医药冷藏集装箱，开展医药"一单制"改革试点，实现不同运输方式无缝衔接。强化数智赋能，建立 省级医药物流信息平台，推动运输全程数据共享，应用区块链技术建立可信追溯体系，推广无人转运 车、智能装卸机器人等装备。 同时，培育专业生态，支持龙头企业与交通平台合作成立医药多式联运运营公司，大力发展"无人机配 送急救药械"等低空经济新模式，拓展"中欧班列+医药冷链"国际物流通道。 "推动医药多式联运高质量发展，需要政府、企业、社会协同发力。"王丁普说， ...

Group 1 - The core theme of the meeting is the deep integration of Dezhou into national and provincial major development strategies, with representatives discussing various proposals to enhance this integration [1] - Dezhou is positioned at the geographical intersection of two national strategies and is seen as a point for policy benefits, prompting suggestions for infrastructure connectivity and collaborative development [2] - The proposal to create a cultural demonstration center along the Grand Canal aims to enhance cultural collaboration among the Beijing-Tianjin-Hebei region and promote the integration of agriculture, culture, and tourism [3] Group 2 - Dezhou has made significant progress in integrating into major development strategies, including the Beijing-Tianjin-Hebei collaborative development, with numerous projects initiated and partnerships established [5] - The city is actively advancing the Yellow River national strategy, with multiple ecological projects underway and a focus on improving environmental quality, evidenced by a 10.2% year-on-year improvement in air quality [6] - Efforts to deepen integration into the Jinan metropolitan area include infrastructure development and educational resource sharing, with several schools and hospitals collaborating across the region [6]

Core Insights - The pharmaceutical logistics industry is experiencing robust growth driven by national policy support, an aging population, increased health awareness, and advancements in medical technology. The "Healthy China" strategy is further enhancing the industry's development space [1][7][9]. Industry Overview - Pharmaceutical logistics is a crucial component of modern logistics, responsible for the circulation and turnover of pharmaceuticals. It encompasses seven main functions: transportation and distribution, warehousing management, packaging, circulation processing, loading and unloading, network design, and information processing [2][5][7]. Market Growth - The total value of pharmaceutical logistics in China has shown steady growth, increasing from 241.86 billion yuan in 2019 to an expected 336.66 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.84%. Projections indicate that this total will reach 357.2 billion yuan by 2025 [1][4][9]. Sales Growth of Pharmaceutical Products - The total sales of seven major categories of pharmaceutical products in China rose from 1,661.3 billion yuan in 2015 to an estimated 2,947.0 billion yuan in 2024, reflecting a CAGR of 6.58%. This expanding market size supports the demand for pharmaceutical logistics [4][9]. Industry Structure - The pharmaceutical logistics industry consists of three main segments: upstream (pharmaceutical manufacturers and equipment suppliers), midstream (logistics companies), and downstream (medical institutions, pharmacies, and patients) [5][6]. Logistics Centers and Warehousing - The number of logistics centers in the pharmaceutical logistics industry increased from 1,115 in 2017 to 1,370 in 2024, with a CAGR of 2.99%. Warehouse area expanded from 10.65 million square meters to 15.42 million square meters during the same period, with a CAGR of 5.43% [10][11]. Transportation Vehicles - The total number of specialized transportation vehicles in the pharmaceutical logistics sector is projected to reach 17,617 by 2024, with refrigerated vehicles accounting for 19.9% of the total, indicating a growing demand for cold chain logistics [12][13]. Delivery Methods and Technology - In 2024, 62.5% of deliveries in the pharmaceutical logistics industry were self-delivered, while 37.5% were outsourced. The adoption of automation and information technology is increasing, with 89.0% of companies having warehouse management systems and 83.1% using electronic tagging systems [13][14]. Key Players - Major companies in the pharmaceutical logistics sector include JD Logistics, China National Pharmaceutical Group, and various specialized logistics firms. JD Logistics reported a revenue of 153.616 billion yuan in the first three quarters of 2025, reflecting a year-on-year growth of 17.5% [14][16]. Industry Challenges - Despite the growth, the pharmaceutical logistics industry faces challenges such as high overall costs, uneven regional development, and a lack of relevant standards [17]. Future Trends - The industry is expected to evolve towards greater automation and intelligence, with AI systems optimizing logistics operations. Additionally, a shift towards full traceability and data integration is anticipated, enhancing the efficiency and responsiveness of the logistics network [18][19].

王 浩 "【提示】2025第八届年度金猿颁奖典礼将在上海举行，此次榜单/奖项的评选依然会进行初审、公审、终审三轮严格评定，并会在国内外渠道大规模发布 传播欢迎申报。 在医药流通行业加速变革、政策监管日趋严格、客户需求愈发多元的当下，医药物流行业的核心竞争力已聚焦于合规保障、效率提升与数据驱动能力的综 合较量。对于上海康展物流有限公司（以下简称上海康展）而言，供应链数智化转型并非简单的技术叠加，而是一场以行业痛点为导向、以客户价值为核 心、以全链路革新为目标的深度变革。我们始终致力于将数智技术深度融入医药物流的每个关键环节，推动企业从传统运营模式向全程可视、智能协同、 合规可控的智慧物流新生态演进。 医药物流的核心痛点，往往源于信息割裂与流程脱节。过去，温控数据滞后、客户协同低效、合规风险加剧等问题，严重制约了行业发展。上海康展的核 心战略，便是打造统一、高效的康展智慧云平台，整合北斗、温控、物联网等技术，打通从订单接收、仓储作业、干线运输到末端配送的全链路数据流， 彻底打破信息壁垒。通过这一平台，我们实现了： 数据互通：整合易流云、必创冷链温湿度监测云平台、ZTMS洲斯等多家监测平台数据，在电脑端与手机端实现 ...

Group 1 - The core point of the article is that Aoyang Health (SZ 002172) held its first board meeting of the tenth session on December 18, 2025, where it reviewed proposals for appointing senior management and other key positions [1] - For the first half of 2025, Aoyang Health's revenue composition was 52.49% from medical services and 47.51% from pharmaceutical logistics [1] - As of the report date, Aoyang Health has a market capitalization of 3.1 billion yuan [1]

Group 1 - The core viewpoint of the article is that Aoyang Health has completed the divestiture of its chemical fiber business and is now focused on medical services and pharmaceutical logistics [1] Group 2 - Aoyang Health's current main business operations are in the fields of medical services and pharmaceutical logistics following the divestiture [1]

Group 1 - The core business scope of the company is medical services and pharmaceutical logistics [1]

Group 1 - The core viewpoint of the article is that Aoyang Health has completed the divestiture of its chemical fiber business and is now focused on medical services and pharmaceutical logistics [1] - Aoyang Health responded to an investor inquiry regarding potential collaboration with Nanjing High Fiber, confirming that there is no ongoing partnership as the chemical fiber business has been divested [1]

Core Viewpoint - Jiangsu Aoyang Health Industry Co., Ltd. has completed the transfer of 20% of its shares to Zhangjiagang Yuesheng Technology Partnership, marking a shift from private to local state-owned control, which may enhance its market position and client trust [1][2][3] Group 1: Share Transfer Details - Aoyang Health's original controlling shareholder, Aoyang Group, transferred 20% of its shares, totaling 153 million shares, at a price of 3.87 yuan per share, amounting to a total of 593 million yuan [1] - The transfer was officially completed on November 6, 2025, with the new controlling entity being Zhangjiagang Economic and Technological Development Zone Management Committee [1] Group 2: Financial Performance - In the first three quarters of 2025, Aoyang Health reported a net profit attributable to shareholders of 40.11 million yuan, a year-on-year increase of 3.71% [2] - The net profit for the third quarter reached 8.56 million yuan, a significant increase of 533.86% compared to the same period last year, marking a new high for recent years [2] Group 3: Strategic Implications of Control Change - The change in control to a local state-owned entity may provide Aoyang Health with enhanced credibility and trust from clients, particularly those with government collaboration interests [2] - The new controlling entity's diverse industry background could facilitate resource integration, potentially enhancing Aoyang Health's capabilities in areas like remote healthcare and smart health monitoring [3] - The shift aligns with national policies promoting integrated medical and elderly care, positioning Aoyang Health to leverage new market opportunities and improve competitive advantage [3]